Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate ...
The CDC revised its pneumococcal pneumonia shot recommendation, saying there is a substantial increase in the risk for infection beginning at age 50.
Antimicrobial resistance and serotypes in Streptococcus pneumoniae have been evolving with the widespread use of antibiotics and the introduction of pneumococcal conjugate vaccines (PCV).
Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD. Just-reported ...
Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data -- -- Company Expects to ...
The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive ...
Beginning at a very young age, babies are vaccinated to prevent more than a dozen serious diseases, and failure to vaccinate ...
Vaxcyte (PCVX) announced that the first study participants have been dosed in the second and final stage of the ongoing Phase 2 study of VAX-31 ...
Medicare Advantage plans, sometimes called Part C, also cover the pneumonia vaccine. Pneumococcal vaccines can prevent common bacterial infections from Streptococcus pneumoniae. There are two ...
Beginning at a very young age, babies are vaccinated to prevent more than a dozen serious diseases, and failure to vaccinate ...
© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...
Advisory Committee on Immunization Practices (ACIP) has lowered the recommended age for pneumococcal vaccination from 65 to ...